Article

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population.

Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 11/2009; 106(48):20365-70. DOI: 10.1073/pnas.0911580106
Source: PubMed

ABSTRACT A major concern about the ongoing swine-origin H1N1 influenza virus (S-OIV) outbreak is that the virus may be so different from seasonal H1N1 that little immune protection exists in the human population. In this study, we examined the molecular basis for pre-existing immunity against S-OIV, namely the recognition of viral immune epitopes by T cells or B cells/antibodies that have been previously primed by circulating influenza strains. Using data from the Immune Epitope Database, we found that only 31% (8/26) of B-cell epitopes present in recently circulating H1N1 strains are conserved in the S-OIV, with only 17% (1/6) conserved in the hemagglutinin (HA) and neuraminidase (NA) surface proteins. In contrast, 69% (54/78) of the epitopes recognized by CD8(+) T cells are completely invariant. We further demonstrate experimentally that some memory T-cell immunity against S-OIV is present in the adult population and that such memory is of similar magnitude as the pre-existing memory against seasonal H1N1 influenza. Because protection from infection is antibody mediated, a new vaccine based on the specific S-OIV HA and NA proteins is likely to be required to prevent infection. However, T cells are known to blunt disease severity. Therefore, the conservation of a large fraction of T-cell epitopes suggests that the severity of an S-OIV infection, as far as it is determined by susceptibility of the virus to immune attack, would not differ much from that of seasonal flu. These results are consistent with reports about disease incidence, severity, and mortality rates associated with human S-OIV.

1 Follower
 · 
121 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The 2009 pandemic H1N1 mainly affected adolescents and children, and most of the elderly in Japan escaped clinical illness. To clarify the role of humoral immunity in the infection, the time kinetics of hemagglutination inhibition (HI), neutralization (NT), and IgG subclass antibody response directed against influenza A(H1N1)pdm2009 were analyzed in three consecutive specimens obtained from 51 young adults and children (group 1) who contracted pandemic influenza and from 74 pediatric clinic employees (group 2) inoculated with pandemic monovalent vaccine. In group 1 patients, 6 and 30 patients had lower HI and NT antibody in the acute phase respectively. Thereafter, HI and NT antibody titers increased fourfold or more in 50 patients with peak response in the third specimens obtained four weeks after the onset. IgG1 in 45 patients, IgG3 in 18 patients, and IgG4 in 29 patients showed elevated responses. Forty (54%) and 70 (95%) subjects in group 2 had positive HI and NT antibodies in the prevaccination samples, with increased antibody responses in the follow-up peaking in the second specimens. Forty of those vaccinated had increased IgG1 responses peaking in the third specimens, whereas elevated IgG3 was observed in 22 recipients with the highest level in the second samples. IgG4 did not show any increase in subjects in group 2. A few participants showed an IgG2 response in both groups. An immunologically naive population contracted influenza with apparent clinical symptoms. However, already primed subjects through subclinical infection elicited the unique pattern of IgG subclass responses by vaccination, which differed from those of naive populations.
    Viral Immunology 09/2014; 27(8). DOI:10.1089/vim.2014.0010 · 1.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza, known as the ‘flu’, is a recurrent acute viral infection that might cause severe inflammation, particularly in vulnerable individuals, i.e. young children, the elderly, and immune-suppressed patients, such as stem cell transplant recipients. Prevention strategies, primarily vaccination, and possibly the use of anti-viral drugs, are recommended with the aim to reduce mortality and morbidity. Influenza vaccination responses are often sub-optimal in immune-compromised patients. There is therefore a need to evaluate other vaccination systems and schedules to improve vaccine efficacy. We mapped the humoral and cellular anti-flu directed immune responses and studied in a first set of experiments the immune responses in immune competent individuals prior to, and following a natural pandemic influenza infection, as well as after adjuvanted Pandemrix® influenza vaccination. This was performed prospectively during the H1N1 pandemic influenza of 2009. ‘High content’ influenza proteome peptide arrays were used to gauge serum IgG epitope signatures prior to and after Pandemrix® vaccination/ or H1N1 pandemic infection described in paper I. A novel epitope residing in the sialic acid receptor-binding domain of VEPGDKITFEATGNL (251-265) of the pandemic flu hemagglutinin was identified. This epitope was found to be exclusively recognized in serum from previously vaccinated individuals and never in serum from individuals with H1N1 infection. The natural H1N1 infection induced a different footprint of IgG epitope recognition patterns as compared to the Pandemrix® H1N1 vaccination. Pre-transplant influenza vaccination of the donor or allogeneic hematopoietic stem cell (HSCT) candidate was evaluated in a randomized study of 122 HSCT patients reported in paper II. The antibody titers against H1 (p=0.028) and H3 (p<0.001) were highest in the pretransplant recipient vaccination group until d.180 after transplantation. A significant difference was found concerning the specific Ig levels against pandemic H1N1 at 6 months after HSCT (p=0.02). The mean IgG levels against pandemic H1N1, generic H1N1 and H3N2 were highest in the pre-transplant recipient vaccination group. Pre-transplant influenza vaccination of the donor or the HSCT candidate was found to be beneficial in eliciting seroprotective titers. The immunogenicity after a single dose of adjuvanted trivalent virosomal vaccination was evaluated in a cohort of 21 HSCT recipients and compared to a control cohort of 30 HSCT recipients who received a single dose of non-adjuvanted seasonal trivalent subunit vaccination, reported in Paper III. The delta change of IFNγ production in response to pandemic influenza H1N1 (p=0.005) and influenza B antigens (p=0.01) were significantly increased in blood from individuals who received the virosomal, as compared to the nonadjuvanted vaccine. Virosomal vaccination was found to be beneficial in eliciting robust cellular immune responses to influenza pandemic H1N1. Pandemic influenza hemagglutinin MHC class 1 peptide restricted CD8 T-cells were enumerated over the course of a natural pandemic influenza infection and Pandemrix® vaccination in a prospective study reported in Paper IV. PBMCs from vaccinated control individuals exhibited a significantly increased percentage of (p=0.003) hemagglutinin specific CD8 T-cells that resided in the terminally differentiated effector memory compartment, as compared to PBMCs from individuals that contracted H1N1 infection. The cellular immune signatures were found to be different elicited by a natural flu infection as compared to vaccination concerning the phenotype/maturation of antigen-specific CD8 Tcells.
    05/2015, Degree: Doctoral Thesis, Supervisor: Prof. Per Ljungman and Prof. Markus Maeurer
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Pre-existing antibodies to influenza virus neuraminidase may provide protection against infection influenza viruses containing novel hemagglutinin (HA). The aim of our study was to evaluate serum neuraminidase-inhibiting (NI) antibodies against А/California/07/2009(H1N1) [H1N1/2009pdm] and А/New Caledonia/20/1999(H1N1) [H1N1/1999] influenza viruses in relation with the age of participants and hemagglutination-inhibition (HI) antibody levels. Anti-H1N1/2009pdm neuraminidase and anti-H1N1/1999 neuraminidase antibody levels were measured in total 219 serum samples from Russian healthy peoples of various ages examined before and a year after pandemic strain appearance. We adjusted peroxidase-linked lectin micro-procedure to measure NI antibody titers using the reassortant A/H7N1 influenza viruses based on A/equine/Prague/1/56(H7N7). Also, HI antibody titers were estimated against H1N1/2009pdm, H1N1/1999 and a panel of seasonal A/H1N1 influenza viruses. Results In sera samples collected during the fall of 2010, mean titers of specific HI and NI antibodies to H1N1/2009pdm were 2–2.1 times lower than antibody levels against H1N1/1999. Of the 163 individuals examined, 58 (35.6%) had NI anti-H1N1/2009pdm antibody titers > 1:20, compared to 93 (57.1%) who had NI anti-H1N1/1999 antibody titers > 1:20. There were low correlations between HI and NI antibody levels against either H1N1/1999 or H1N1/2009pdm in the same serum samples. The 24 adults born between 1957 and 1977 expressed very low levels of NI antibodies to A/H1N1 influenza viruses. Persons with low HI anti-H1N1/2009pdm titers but positive to seasonal A/H1N1 demonstrated significantly higher NI anti-A/H1N1 antibody titers than unexposed subjects. In 2005 cross-reactive NI anti-H1N1/2009pdm antibody titers > 1:20 were detected among 7.1% of young people. Conclusions Our study confirmed that contact with seasonal influenza viruses may have contributed to generating the cross-reacting anti-H1N1/2009pdm NI antibodies which were detected in the sera of 18-20 years old people examined before the pandemic virus active circulation. The lowest levels of antibodies to the neuraminidase of N1 subtype were in the group of participants born during the circulation of influenza A/H2N2 or A/H3N2 viruses. The low correlation between HI and NI antibody titers suggests that NI antibody detection can be used as an additional test to evaluate the immune response after influenza infections or immunizations.
    BMC Research Notes 04/2015; 8(1). DOI:10.1186/s13104-015-1086-z

Full-text (2 Sources)

Download
38 Downloads
Available from
May 23, 2014